Leo Linbeck IV

Executive Officer at Goldenrod Therapeutics.

Raised on Goldenrod Therapeutics filings

$3.2M

of $6.5M offered across 1 Form D filing

Form D filings: 1
Teammates: 6
Last filing: Jun 3, 2026

Company

Goldenrod Therapeutics

Biotech · Houston, TX

Brain-penetrant small molecule for Friedreich's ataxia

Brain-penetrant small molecule for Friedreich's ataxia

Investors: 2
Founded: 2023
Still open: $3.3M

Investors: 2
Sector: Biotech
Founded: 2023
HQ: Houston, TX

Goldenrod Therapeutics filings

Goldenrod Therapeutics Form D filings
Filed	Security	Sold of offered	Filing
Jun 3, 2026	Equity	$3.2M/ $6.5M	Form D

EquityFiled Jun 3, 2026Form D
$3.2M/ $6.5M

Works with

Also named on Goldenrod Therapeutics filings

Jordan LeePOA from Atul Varadhachary, Form D signerForm D signer Mark WorschehExecutive Officer, Director Atul VaradhacharyExecutive Officer, Director Dev ChatterjeeExecutive Officer Leo Linbeck IIIDirector Thomas BrenninkmeijerDirector